Trial Profile
Phase II Multicenter Study to Analyze the Predictive Value of Fusion Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Metastatic CRPC no Previously Treated With Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PREMIERE; PREMIERE-SOGUG
- 20 Sep 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results (n=98) assessing the predictive/prognostic value of TMPRSS2-ERG fusion gene in first-line metastatic castration-resistant prostate cancer patients treated with enzalutamide presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 06 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019.